Harvard Bioscience Inc (HBIO) 13F Holdings Overview (Q2 2026)

HBIO ranks #7090 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

HBIO is a disclosed holding of Two Sigma (Two Sigma Investments), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

35 institutions disclose a position in HBIO, but none treat it as a major bet — even Weber Capital Management LLC /adv, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

HBIO reported a net loss of $10.4M over the trailing twelve months.

• Not yet profitable — net loss of $10.4M over the trailing twelve months
• Revenue declined 1.1% year over year
• Net income improved year over year, from -$57.4M to -$10.4M
• Generated $6.7M in positive operating cash flow
• Current ratio of 2.20x — enough short-term assets to cover short-term liabilities
• Liabilities run 4.83x equity — a highly leveraged balance sheet worth noting